-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ozanimod is a selective sphingosine-1 phosphate receptor modulator and is currently being explored for its effectiveness in the treatment of inflammatory bowel disease
.
Recently, a research article was published in the top medical journal NEJM.
Researchers conducted a phase 3, multicenter, randomized, double-blind, multicenter, randomized, double-blind, phase 3, multi-center, randomized, double-blind, phase 3, multicenter, randomized, double-blind, induction and maintenance treatment for patients with moderate to severe active ulcerative colitis .
Placebo controlled trial
.
During the 10-week induction period, patients in cohort 1 were assigned to receive 1 mg of Ozanimod or placebo daily in a double-blind manner, while patients in cohort 2 received the same dose of Ozanimod in the open group
.
At week 10, patients in either cohort who had a clinical response to Ozanimod were randomized again and received double-blind Ozanimod or placebo treatment during the maintenance period (until week 52)
During the induction period, 645 patients were enrolled in cohort 1 and 367 patients were enrolled in cohort 2; a total of 457 patients were enrolled in the maintenance period
.
In the induction phase (18.
Infect
It can be seen that Ozanimod is more effective than placebo as an induction and maintenance treatment for patients with moderate to severe active ulcerative colitis
.
.
Original source:
William J.
Sandborn, et al.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis .
